Carfilzomib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1699 publications

Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients.

Development and Validation of a Rapid LC-MS/MS Method for Carfilzomib Quantification in Plasma from Multiple Myeloma Patients.

Journal: Journal of visualized experiments : JoVE

Published: June 01, 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine

Published: May 29, 2026

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases.

Journal: medRxiv : the preprint server for health sciences

Published: May 25, 2026

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.

Correction to 'Mucin 20 Modulates Proteasome Capacity Through c-Met Signalling to Increase Carfilzomib Sensitivity in Mantle Cell Lymphoma'.

Journal: Journal of cellular and molecular medicine

Published: May 19, 2026

Turning adaptive resistance into vulnerability: AUTAC-Mediated degradation of Mcl1.

Turning adaptive resistance into vulnerability: AUTAC-Mediated degradation of Mcl1.

Journal: Autophagy

Published: May 04, 2026

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial.

Journal: Lancet (London, England)

Published: April 29, 2026

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Journal: Future oncology (London, England)

Published: April 13, 2026

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma.

Journal: Cells

Published: April 02, 2026

Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.

Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance.

Journal: Biochemical pharmacology

Published: March 25, 2026

Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma.

Proteasome Targeting with Carfilzomib Induces Reactive Oxygen Species-Mediated Apoptosis in Hepatoblastoma.

Journal: Cells

Published: March 25, 2026

Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma.

Design, radiolabeling, and biological evaluation of a novel 177Lu-AAZTA5-Carfilzomib conjugate as a proteasome-targeted theranostic agent for multiple myeloma.

Journal: Journal of pharmaceutical sciences

Published: March 24, 2026

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Journal: Zhongguo shi yan xue ye xue za zhi

Published: March 18, 2026

Showing 1-12 of 1,699

Last Updated: 06/30/2026